Panelists Discuss Insurance Coverage of Opill, OTC Contraceptives During KFF Webinar
September 21st 2023Laurie Sobel, the associate director for women’s health policy at KFF, moderated a panel discussion with Christine Gilroy, MD, MPH; Victoria Nichols, MPH; and Don Downing, RPh, about insurance coverage of FDA-approved Opill and other OTC contraceptives.
Read More
Tailored EHR Alerts Fail to Improve Acute HF Medication Prescription at Discharge
September 21st 2023A tailored electronic health record (EHR) alert system did not significantly increase the prescription of guideline-directed medical therapies (GDMT) at hospital discharge for patients with acute heart failure (AHF).
Read More
What We’re Reading: Free COVID-19 Tests; Vaccine Distrust; FDA Rejects Epinephrine Spray
September 21st 2023The Biden administration will once again provide free COVID-19 tests for Americans; vaccine skepticism exists on both sides of the presidential race, concerning health officials; the FDA denied an application for the first nasal spray to treat allergic reactions, including anaphylaxis.
Read More
Dr Kristin Oaks: Value-Based Care Allows Us to Support Our Sickest Patients
September 21st 2023Kristin Oaks, DO, Agilon regional medical director at Central Ohio Primary Care, spoke at our recent Institute for Value-Based Medicine® event held with Zangmeister Cancer Center. Here, she addresses the importance of value-based care within the primary care space.
Watch
Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL
September 21st 2023Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.
Read More
First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC
September 20th 2023In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).
Read More
Dr Erin Gillaspie Explains How to Discover Best Treatments for Patients With Lung Cancer
September 20th 2023Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, explained what testing needs to be done to identify the best treatment for patients with lung cancer.
Watch
Most people don’t know they have hypertension, and a new recommendation advises that pregnant women should be screened for blood pressure disorders at every appointment; patients in primary care face long wait times, which may be due to physician incentives under value-based payments; a lawsuit in New Jersey targets the residency requirement to allow aid in dying for those out of state.
Read More
COA’s Nick Ferreyros Addresses Oncology Policy Changes and the IRA
September 20th 2023We are in the midst of a transformative time in oncology that could also be a little scary if you are not prepared, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.
Watch
Adalimumab Plus Surgery Delivers Better Outcomes Than Adalimumab Alone for HS
September 19th 2023Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with adalimumab alone.
Read More
Incidence Rate of Tuberculosis Among Individuals With HIV in Africa Higher Than Estimated
September 19th 2023The World Health Organization 2022 Africa regional report underestimated the incidence rate of tuberculosis in sub-Saharan African individuals living with HIV, according to a recent analysis.
Read More
Dr Ryan Haumschild Discusses Payer, Provider Perspectives on Prior Authorization in Rare Diseases
September 19th 2023Ryan Haumschild, PharmD, MS, MBA, director of pharmacy at Emory Winship Cancer Institute, shares his unique perspectives as both a provider and payer on the use of prior authorizations (PAs) and "Gold Cards" in patients with rare diseases.
Watch
What We’re Reading: Health Programs Threatened; Midwives Needed; Sleep Deprivation and Screen Time
September 19th 2023Various health programs may shut down at the end of September without congressional action; maternal health experts push for midwife workforce expansion amidst high maternal mortality rates in the United States; studies find that heightened screen time in teens and tweens before bed can result in a lack of sleep.
Read More
Relative Benefit in Survival, Reduction in TE/MAVE Risk With Eculizumab for Patients With PNH
September 19th 2023When patients with paroxysmal nocturnal hemoglobinuria (PNH) received eculizumab, survival rates increased and thromboembolic events/major adverse vascular events (TE/MAVE) decreased.
Read More
NCCN Working Group Presents Health-Related Social Needs Recommendations at Policy Summit
September 19th 2023During this session at the National Comprehensive Cancer Network (NCCN) Policy Summit, Yelak Biru, MSc, and Crystal S. Denlinger, MD, explained the importance of screening for and addressing health-related social needs.
Read More
Dr Kristine Slam: Value-Based Care in Breast Cancer Requires Collaboration
September 19th 2023In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.
Watch